DNLI250117C45000
- 0.00
- 0.000.00%
Denali Therapeutics Newsroom
Stifel Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Denali Therapeutics Maintains Strong Buy Rating Amid Setbacks, Fueled by Promising BBB Platform
Stifel Likes Denali Therapeutics on Weakness
Denali Therapeutics Says ALS Trial Didn't Meet Endpoints
Express News | Denali Therapeutics Inc - Dnl343 Found to Be Safe and Well Tolerated
Express News | Denali Therapeutics Inc - Study Did Not Meet Primary Endpoint of Slowing Disease Progression
Express News | Denali Therapeutics Announces Topline Results for Regimen G Evaluating Eif2B Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial
Denali Therapeutics Announces Topline Results for Regimen G Evaluating EIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Insider Sale: Director at $DNLI (DNLI) Sells 30,000 Shares
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
William Blair Initiates Coverage On Denali Therapeutics With Outperform Rating
William Blair Initiates Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $35
Insiders At Denali Therapeutics Sold US$1.8m In Stock, Alluding To Potential Weakness
Denali Therapeutics Upgraded to Buy From Hold at Stifel
Stifel Upgrades Denali Therapeutics(DNLI.US) to Buy Rating, Raises Target Price to $37
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target
Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease